Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Deciphera Pharmaceuticals, Inc.
  6. News
  7. Summary
    DCPH   US24344T1016

DECIPHERA PHARMACEUTICALS, INC.

(DCPH)
  Report
Delayed Nasdaq  -  04:00:00 2023-01-27 pm EST
17.31 USD   -3.73%
01/25Cowen Adjusts Price Target on Deciphera Pharmaceuticals to $30 From $25, Maintains Outperform Rating
MT
01/24Deciphera Pharmaceuticals Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session
BU
01/24Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
BU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Transcript : Deciphera Pharmaceuticals, Inc., Q3 2022 Earnings Call, Nov 03, 2022

11/03/2022 | 07:00am EST
share with twitter
share with LinkedIn
share with facebook
Good morning, everyone, and welcome to the Deciphera Pharmaceuticals Third Quarter 2022 Financial Results Conference Call. Today's call is being recorded. At this time, I would like to turn the call...


© S&P Capital IQ 2022
All news about DECIPHERA PHARMACEUTICALS, INC.
01/25Cowen Adjusts Price Target on Deciphera Pharmaceuticals to $30 From $25, Maintains Outp..
MT
01/24Deciphera Pharmaceuticals Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clin..
BU
01/24Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full..
BU
01/24Deciphera Pharmaceuticals, Inc. Presents Results from ctDNA Analysis of INTRIGUE Phase ..
CI
01/23Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
AQ
01/20Deciphera Pharmaceuticals, Inc. : Entry into a Material Definitive Agreement, Financial St..
AQ
01/20Deciphera Pharmaceuticals Prices $125 Million Common Stock Offering
MT
01/19Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
BU
01/19Sector Update: Health Care Stocks Flat to Lower Pre-Bell Thursday
MT
01/19Deciphera Pharmaceuticals Plans $125 Million Common Stock Offering -- Shares Down Pre-B..
MT
More news
Analyst Recommendations on DECIPHERA PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 133 M - -
Net income 2022 -177 M - -
Net cash 2022 91,0 M - -
P/E ratio 2022 -6,98x
Yield 2022 -
Capitalization 1 305 M 1 305 M -
EV / Sales 2022 9,11x
EV / Sales 2023 7,86x
Nbr of Employees 280
Free-Float 66,0%
Chart DECIPHERA PHARMACEUTICALS, INC.
Duration : Period :
Deciphera Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DECIPHERA PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 17,31 $
Average target price 21,60 $
Spread / Average Target 24,8%
EPS Revisions
Managers and Directors
Steven L. Hoerter President & Chief Executive Officer
Thomas P. Kelly Chief Financial Officer, Treasurer & Executive VP
James A. Bristol Chairman
Daniel L. Flynn President, Chief Executive Officer & Director
Stephen B. Ruddy Chief Technical Officer & SVP
Sector and Competitors
1st jan.Capi. (M$)
DECIPHERA PHARMACEUTICALS, INC.9.70%1 305
VERTEX PHARMACEUTICALS11.16%82 513
REGENERON PHARMACEUTICALS, INC.2.88%79 336
WUXI APPTEC CO., LTD.20.37%42 407
BIONTECH SE-4.37%34 912
BEIGENE, LTD.18.12%27 008